Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comprehensive Comparative Effectiveness Program Continues To Be Goal For Congress

This article was originally published in The Pink Sheet Daily

Executive Summary

The $1.1 billion for CE in the stimulus package is a “down payment” on a long-term effort, congressional staffers tell an IOM committee

You may also be interested in...



Baucus to Proceed With Public/Private Comparative Effectiveness Vision

Even with the inclusion of comparative effectiveness research funding in the American Recovery and Reinvestment Act, Senate Finance Committee Chairman Max Baucus is showing no signs of abandoning plans to include comparative effectiveness in the upcoming health care reform debate

Comparative Effectiveness Language Clarified In Compromise Stimulus Bill

Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel